26 related articles for article (PubMed ID: 16205769)
1. Molecular and pathobiological insights of bikunin/UTI in cancer.
Lepedda AJ; Nieddu G; Cannas C; Formato M
Mol Biol Rep; 2023 Feb; 50(2):1701-1711. PubMed ID: 36414878
[TBL] [Abstract][Full Text] [Related]
2. Plasma bikunin as a favorable prognostic factor in ovarian cancer.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
J Clin Oncol; 2005 Mar; 23(7):1463-72. PubMed ID: 15735122
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer.
Tanaka Y; Kobayashi H; Suzuki M; Kanayama N; Suzuki M; Terao T
Gynecol Oncol; 2004 Sep; 94(3):725-34. PubMed ID: 15350365
[TBL] [Abstract][Full Text] [Related]
4. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study.
Polterauer S; Grimm C; Seebacher V; Concin N; Marth C; Tomovski C; Husslein H; Leipold H; Hefler-Frischmuth K; Tempfer C; Reinthaller A; Hefler L
Oncologist; 2009 Oct; 14(10):979-85. PubMed ID: 19776095
[TBL] [Abstract][Full Text] [Related]
5. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
Borgoño CA; Kishi T; Scorilas A; Harbeck N; Dorn J; Schmalfeldt B; Schmitt M; Diamandis EP
Clin Cancer Res; 2006 Mar; 12(5):1487-93. PubMed ID: 16533772
[TBL] [Abstract][Full Text] [Related]
6. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
Begum FD; Høgdall E; Kjaer SK; Blaakaer J; Christensen IJ; Christensen L; Høgdall C
Gynecol Oncol; 2009 May; 113(2):221-7. PubMed ID: 19261323
[TBL] [Abstract][Full Text] [Related]
7. Could high plasma bikunin predict a favorable outcome in ovarian cancer?
McIntosh M
Nat Clin Pract Oncol; 2005 Oct; 2(10):502-3. PubMed ID: 16205769
[No Abstract] [Full Text] [Related]
8. The protease inhibitor bikunin, a novel anti-metastatic agent.
Kobayashi H; Suzuki M; Hirashima Y; Terao T
Biol Chem; 2003 May; 384(5):749-54. PubMed ID: 12817471
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer. It whispers ... so listen!
Gill MA
Adv Nurse Pract; 1998 Nov; 6(11):48, 50, 52-4. PubMed ID: 9919060
[No Abstract] [Full Text] [Related]
10. Managing ovarian cancer--a GP guide.
Brinkmann D; Jacobs I
Practitioner; 2001 Apr; 245(1621):276-9, 281-2, 286. PubMed ID: 11332002
[No Abstract] [Full Text] [Related]
11. [Biological factors with prognostic significance in ovarian cancer].
Ferrandina G; Legge F; Fagotti A; Fanfani F; Mancuso S; Scambia G
Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):40-5. PubMed ID: 11526718
[No Abstract] [Full Text] [Related]
12. Idiopathic urinary stone disease: possible polygenic aetiological factors.
Watts RW
QJM; 2005 Apr; 98(4):241-6. PubMed ID: 15781479
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
